about
Update on biomarkers in systemic sclerosis: tools for diagnosis and treatmentRapid, noninvasive quantitation of skin disease in systemic sclerosis using optical coherence elastography.Pressure and pain in systemic sclerosis/scleroderma--an evaluation of a simple intervention (PISCES): randomised controlled trial protocolImprovement of microstomia in scleroderma after intense pulsed light: A case series of four patients.Effects of intense pulsed light in microstomia in patients with systemic sclerosis: A pilot study.Guidelines of the Brazilian society of bone Marrow transplantation on hematopoietic stem cell transplantation as a treatment for the autoimmune diseases systemic sclerosis and multiple sclerosis.Recognizing systemic sclerosis: comparative analysis of various sets of classification criteria.Rheumatic manifestations of skin disease.Biomarkers for skin involvement and fibrotic activity in scleroderma.N-TproBNP as biomarker in systemic sclerosis.Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development.Quantitating skin fibrosis: innovative strategies and their clinical implications.Ultrasound in systemic sclerosis. A multi-target approach from joint to lung.Phototherapy in systemic sclerosis: Review.Digital ulcers in scleroderma patients: A retrospective observational study.Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis.Subclinical dermal involvement is detectable by high frequency ultrasound even in patients with limited cutaneous systemic sclerosis.Spontaneous skin regression and predictors of skin regression in Thai scleroderma patients.High frequency ultrasound can detect improvement of lesions in juvenile localized scleroderma.Assessment of skin involvement in systemic sclerosis.Clinical utility of hypo- and hyperpigmentation of skin in diffuse cutaneous systemic sclerosis.European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes.Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
P2860
Q26995542-6DE0BA75-11BC-418E-AE6A-DD9B097DD75EQ30744824-6918F35F-B6F1-4DC3-8214-EED6A50FC1EAQ34152046-CCE2EB08-E0D0-4127-B12B-3E5E6DB7807EQ34188674-DD34B50B-A92B-4C32-9289-76EFE83E60A5Q36211656-9F9FBF29-923B-468C-848C-7318C9029865Q36901406-0E51AAF4-BD7B-4CB7-BAAE-C45E62ACC9A4Q37590671-50896FCC-2401-480C-A451-798AC0D4364FQ37620086-3AF537D3-ED0C-4CE7-BD7F-B47B41E0F5DFQ37912251-72D7946F-6F22-499B-A74E-8E21BF86C466Q38016375-FAC98376-6E32-4F9D-B0E5-C560B9DD0E7FQ38156227-CC2D7B73-4476-4DFF-A5CC-35F6C457A6FDQ38180018-008468D2-7F00-4AF2-BC63-860007CD6610Q38188843-56DD58E1-7885-49C4-87EF-5986B974FD7FQ39432364-DB1C2570-55B4-40D8-B9A9-35FDE891BBBAQ40192330-7363FE82-B5EF-45CD-AD2E-984F626B8D5CQ41066068-256DC3C5-9C2E-47F7-8F35-59853D96BCE0Q42314961-2D583B4A-B2AF-4FA4-9621-2FE594A2C0A8Q43875422-62EFBA5D-3B78-4131-AF6D-8B780545F641Q45073477-F5C4EFFE-6D49-4D86-965F-74BC188CDB80Q47835767-7B6A1930-2ABD-4CAA-81EC-F4133FE00E8CQ47839424-18A76831-6690-4E0B-BA36-D95BFBD3339AQ49072027-A1ABEA33-9523-4A3E-B636-5F1E3B907076Q52880098-5DFF2CAB-3E72-41F7-ADD9-3C31B5359E96
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Skin involvement in systemic sclerosis.
@en
Skin involvement in systemic sclerosis.
@nl
type
label
Skin involvement in systemic sclerosis.
@en
Skin involvement in systemic sclerosis.
@nl
prefLabel
Skin involvement in systemic sclerosis.
@en
Skin involvement in systemic sclerosis.
@nl
P2860
P356
P1433
P1476
Skin involvement in systemic sclerosis.
@en
P2093
I Foeldvari
P2860
P356
10.1093/RHEUMATOLOGY/KEN309
P478
47 Suppl 5
P577
2008-10-01T00:00:00Z